Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders.

Yi B, Jahangir A, Evans AK, Briggs D, Ravina K, Ernest J, Farimani AB, Sun W, Rajadas J, Green M, Feinberg EN, Pande VS, Shamloo M.

PLoS One. 2017 Jul 26;12(7):e0180319. doi: 10.1371/journal.pone.0180319. eCollection 2017.

2.

Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist.

Ardestani PM, Evans AK, Yi B, Nguyen T, Coutellier L, Shamloo M.

Neuropharmacology. 2017 Apr;116:371-386. doi: 10.1016/j.neuropharm.2017.01.010. Epub 2017 Jan 13.

3.

Norepinephrine differentially modulates the innate inflammatory response provoked by amyloid-β peptide via action at β-adrenoceptors and activation of cAMP/PKA pathway in human THP-1 macrophages.

Yang JH, Lee EO, Kim SE, Suh YH, Chong YH.

Exp Neurol. 2012 Aug;236(2):199-206. doi: 10.1016/j.expneurol.2012.05.008. Epub 2012 May 15.

PMID:
22609331
4.

Distinct adrenergic system changes and neuroinflammation in response to induced locus ceruleus degeneration in APP/PS1 transgenic mice.

Jardanhazi-Kurutz D, Kummer MP, Terwel D, Vogel K, Thiele A, Heneka MT.

Neuroscience. 2011 Mar 10;176:396-407. doi: 10.1016/j.neuroscience.2010.11.052. Epub 2010 Dec 1.

PMID:
21129451
5.
6.

Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity.

Counts SE, Mufson EJ.

J Neurochem. 2010 May;113(3):649-60. doi: 10.1111/j.1471-4159.2010.06622.x. Epub 2010 Feb 1.

7.

Inhibition of LTP by beta-amyloid is prevented by activation of beta2 adrenoceptors and stimulation of the cAMP/PKA signalling pathway.

Wang QW, Rowan MJ, Anwyl R.

Neurobiol Aging. 2009 Oct;30(10):1608-13. doi: 10.1016/j.neurobiolaging.2007.12.004. Epub 2008 Feb 12.

PMID:
18272254
8.

Polymorphism in genes involved in adrenergic signaling associated with Alzheimer's.

Bullido MJ, Ramos MC, Ruiz-Gómez A, Tutor AS, Sastre I, Frank A, Coria F, Gil P, Mayor F Jr, Valdivieso F.

Neurobiol Aging. 2004 Aug;25(7):853-9.

PMID:
15212839
9.

Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages.

Wu YH, Feenstra MG, Zhou JN, Liu RY, Toranõ JS, Van Kan HJ, Fischer DF, Ravid R, Swaab DF.

J Clin Endocrinol Metab. 2003 Dec;88(12):5898-906.

PMID:
14671188
10.

Protein targeting to glycogen mRNA expression is stimulated by noradrenaline in mouse cortical astrocytes.

Allaman I, Pellerin L, Magistretti PJ.

Glia. 2000 Jun;30(4):382-91.

PMID:
10797618
11.

The effect of hydrogen peroxide upon beta-adrenoceptor density and function in C6 rat glioma cells.

Bergström D, Jacobsson SO, Fowler CJ.

Neurochem Int. 1999 Jan;34(1):63-70.

PMID:
10100197
12.

Disrupted beta 1-adrenoceptor-G protein coupling in the temporal cortex of patients with Alzheimer's disease.

Cowburn RF, Vestling M, Fowler CJ, Ravid R, Winblad B, O'Neill C.

Neurosci Lett. 1993 Jun 11;155(2):163-6.

PMID:
8397350
13.

Beta-adrenoceptor density and subtype distribution in cerebellum and hippocampus from patients with Alzheimer's disease.

Lemmer B, Langer L, Ohm T, Bohl J.

Naunyn Schmiedebergs Arch Pharmacol. 1993 Feb;347(2):214-9.

PMID:
8097284
14.

Adrenergic receptors in aging and Alzheimer's disease: increased beta 2-receptors in prefrontal cortex and hippocampus.

Kalaria RN, Andorn AC, Tabaton M, Whitehouse PJ, Harik SI, Unnerstall JR.

J Neurochem. 1989 Dec;53(6):1772-81.

PMID:
2553864
15.
16.

Changes in beta-adrenergic receptor subtypes in Alzheimer-type dementia.

Shimohama S, Taniguchi T, Fujiwara M, Kameyama M.

J Neurochem. 1987 Apr;48(4):1215-21.

PMID:
3029330

Supplemental Content

Loading ...
Support Center